D.E. Shaw & Co
VOR icon

D.E. Shaw & Co’s Vor Biopharma VOR Stock Holding History

D.E. Shaw & Co’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
+54,671
New +$827K ﹤0.01% 3747
2023
Q2 		– Sell
-574
Closed -$61.8K – 4583
2023
Q1 		$61.8K Sell
574
-1,971
-77% -$218K ﹤0.01% 4019
2022
Q4 		$338K Buy
+2,545
New +$252K ﹤0.01% 4040

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co's VOR Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Vor Biopharma (VOR) in Q2 2026: 54,671 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #3747 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in VOR as recently as Q1 2023.

D.E. Shaw & Co first reported a position in VOR in Q4 2022 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • D.E. Shaw & Co held 54,671 shares of Vor Biopharma worth $1.01M as of Q2 2026.
  • Vor Biopharma was a new D.E. Shaw & Co position in Q2 2026.
  • Vor Biopharma made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3747 holding.
  • D.E. Shaw & Co first reported a position in Vor Biopharma in Q4 2022 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.